Abstract: The present invention relates to a kit of in vitro quantifying large surface protein of hepatitis B virus (LHBS). The kit includes monoclonal antibodies having respective binding specificity for specific regions of LHBS, thereby increasing sensitivity and dynamic breadth of detecting LHBS in a biological sample. Moreover, the invention also provides a biomarker set corresponding to the specific regions of LHBS, and the biomarker set can be specifically recognized by the monoclonal antibodies, for non-invasively analyzing phases of HBV infection and hepatoma prognosis in a biological sample. Furthermore, the invention also provides a set of monoclonal antibodies for predicting, diagnosing or treating a chronic liver disease via those biomarkers in a subject in need thereof.

Abstract: The disclosure provides a method for estimating a risk for a subject suffering from hepatocellular carcinoma, including: (a) determining methylation levels of APC gene, COX2 gene, RASSF1A gene and micro RNA-203 gene in a sample of a subject, respectively; (b) calculating a predicted score according to the methylation levels of the APC gene, COX2 gene, RASSF1A gene and micro RNA-203 gene; and (c) estimating a risk level for the subject suffering from hepatocellular carcinoma according to the predicted score.